Multi-analyte ADC PK/PD and exposure-driven dose selection — therapeutic window and OBD from conjugate efficacy vs. free-payload toxicity, the toxicology paradigm (not MABEL).

Mechanistic first-in-human dosability screen for tumor-targeted bispecific antibodies — go/no-go and dosability-margin ranking computed from binding parameters, before any dose exists.